chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 65.0
Sex: F
Vaccine: COVID19, COVID19, COVID19-2, COVID19
Symptoms: No adverse event, Underdose
Clinical narrative: No adverse event; The patient thinks that may have received a full dose instead of a half dose; This spontaneous case was reported by a patient and describes the occurrence of INCORRECT DOSE ADMINISTERED (The patient thinks that may have received a full dose instead of a half dose) and NO ADVERSE EVENT (No adverse event) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039D21A, 012M20A and 043L20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INCORRECT DOSE ADMINISTERED (The patient thinks that may have received a full dose instead of a half dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (The patient thinks that may have received a full dose instead of a half dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            Concomitant drugs were not reported. Treatment medications were not provided. Patient did not remember which arm she received the vaccine in.   This case was linked to MOD-2022-658743, MOD-2022-658756 (Patient Link).
Age: 65.0
Sex: F
Vaccine: COVID19, COVID19, COVID19-2, COVID19
Symptoms: Arthralgia, Vaccination site pain
Clinical narrative: No adverse event; The patient thinks that may have received a full dose instead of a half dose; This spontaneous case was reported by a patient and describes the occurrence of INCORRECT DOSE ADMINISTERED (The patient thinks that may have received a full dose instead of a half dose) and NO ADVERSE EVENT (No adverse event) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039D21A, 012M20A and 043L20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INCORRECT DOSE ADMINISTERED (The patient thinks that may have received a full dose instead of a half dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (The patient thinks that may have received a full dose instead of a half dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            Concomitant drugs were not reported. Treatment medications were not provided. Patient did not remember which arm she received the vaccine in.   This case was linked to MOD-2022-658743, MOD-2022-658756 (Patient Link).
Age: 0.83
Sex: M
Vaccine: FLU4
Symptoms: Accidental exposure to product, Expired product administered
Clinical narrative: nadvertently given expired product with no reported adverse event; nadvertently given expired product with no reported adverse event; Initial information received on 10-Oct-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case is linked to cases 2022SA419169(CLUSTER) and 2022SA420010(CLUSTER).  This case involves a 10 months old male patient who was inadvertently given expired product with no reported adverse event ,after receiving vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QIV].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 07-Oct-2022, the patient received a total dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot UT7378MA and expiration date: 30-Jun-2024) at a dose of 0.5ml once via intramuscular route in the vastus lateralis for immunization.  On 07-Oct-2022(latency: same day), the patient was inadvertently given expired product with no reported adverse event (expired product administered) (accidental exposure to product) following the administration.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events.   Outcome: unknown for both events   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: 1st dose over 4 years ago, 2nd not received; This case was reported by a consumer via interactive digital media and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (had 1st dose of shingles vaccine over 4 years ago).   On an unknown date, the patient did not receive the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 07-OCT-2022 Reporter's Comment: This case was received from the patient via interactive digital media. The reporter wanted to know if a second shot of shingles vaccine gave him/her protection or would he/she need to start over again. Additional Supportive Information: Till the time of reporting, the patient did not receive the 2nd shot of shingles vaccine, which led to incomplete course of vaccination. The case had been linked to US2022AMR144730,reported by the same reporter, for different patients. The follow up would not possible as no contact details were available.; Sender's Comments:  US-GSK-US2022AMR144730:Same reporter / master file
Sex: U
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: 1st dose over 4 years ago, 2nd not received; This case was reported by a consumer via interactive digital media and described the occurrence of incomplete course of vaccination in an unspecified number of patients who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (had 1st dose of shingles vaccine over 4 years ago).   On an unknown date, the patient did not receive the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 07-OCT-2022 Reporter's Comment: This case was received from the consumer via interactive digital media. The reporter wanted to know if a second shot of shingles vaccine gave us protection or would we need to start over again. Additional Supportive Information: Till the time of reporting, the patients did not receive the 2nd shot of shingles vaccine, which led to incomplete course of vaccination. The case had been linked to US2022AMR144728, reported by the same reporter, for different patient. The follow up would not possible as no contact details were available.; Sender's Comments:  US-GSK-US2022AMR144728:Same reporter
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus, Rash, Scratch
Clinical narrative: rash; It has itched; It has scratched; This case was reported by a consumer via interactive digital media and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, 1 day after receiving Shingrix, the patient experienced rash, pruritus and scratch. On an unknown date, the outcome of the rash, pruritus and scratch were recovered/resolved.   The reporter considered the rash, pruritus and scratch to be possibly related to Shingrix.     Additional Information: GSK Receipt Date: 26-SEP-2022 Reporter's Comments:  This case was received from Consumer via interactive digital media. The nurse mentioned to patient that she might get a rash post  vaccination. The Shingles booster caused to break out her in rash, the next day. It itched and scratched for 3 weeks. The follow up would not possible as no contact details were available.
Sex: F
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: 1st dose on 21Jun2021, 2nd not received; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose of Shingrix on 21st June 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 07-OCT-2022 Reporter's Comment: The patient had not received 2nd dose of Shingrix yet. The vaccine administration facility was the same as primary reporter. The healthcare professional ended chat before answering if follow up was ok. Additional Supportive Information: Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination. The VAERS details were provided for 1st dose of Shingrix.
Age: 24.0
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No Adverse event; monovalent vaccine for 6-11 years old administered instead of bivalent vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (monovalent vaccine for 6-11 years old administered instead of bivalent vaccine) and NO ADVERSE EVENT (No Adverse event) in a 24-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR6965B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Oct-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 08-Oct-2022, the patient experienced WRONG PRODUCT ADMINISTERED (monovalent vaccine for 6-11 years old administered instead of bivalent vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (monovalent vaccine for 6-11 years old administered instead of bivalent vaccine) and NO ADVERSE EVENT (No Adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (monovalent vaccine for 6-11 years old administered instead of bivalent vaccine).    Concomitant medication details was not reported.  The patient received 0.5ml of the dark blue cap vaccine that was intended for use in 6-11 years old age patient, instead of the new bivalent vaccine.  Treatment details was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2022-657506 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-657506:Master case (Crosslink case with same reporter)
Sex: M
Vaccine: COVID19
Symptoms: Somnolence
Clinical narrative: Patient felt very sleepy; This spontaneous case was reported by a patient family member or friend and describes the occurrence of SOMNOLENCE (Patient felt very sleepy) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (Patient felt very sleepy). At the time of the report, SOMNOLENCE (Patient felt very sleepy) outcome was unknown.            It was unknown if any treatment was given or if patient was under any concomitant or regular medication.   This case was linked to US-MODERNATX, INC.-MOD-2022-658060 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-658060:
Sex: U
Vaccine: COVID19
Symptoms: Accidental underdose, No adverse event
Clinical narrative: No adverse event; Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 12-Oct-2022, the patient experienced ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (Received 0.25 ml dose instead of 0.5 ml for Bivalent Booster).    Concomitant drugs were not reported. It was reported that patient received 0.25 mL of bivalent booster dose instead of 0.5 mL and stated that reporter called the CDC and were instructed to go ahead and administer the other half of the dose on the same day. Treatment medications were not provided. This case was reported for the adult patient 11.   This case was linked to US-MODERNATX, INC.-MOD-2022-658149, US-MODERNATX, INC.-MOD-2022-658139, US-MODERNATX, INC.-MOD-2022-658150, US-MODERNATX, INC.-MOD-2022-658155, US-MODERNATX, INC.-MOD-2022-658154, US-MODERNATX, INC.-MOD-2022-658156, US-MODERNATX, INC.-MOD-2022-658157, US-MODERNATX, INC.-MOD-2022-658159, US-MODERNATX, INC.-MOD-2022-658162, US-MODERNATX, INC.-MOD-2022-658168, US-MODERNATX, INC.-MOD-2022-658173, US-MODERNATX, INC.-MOD-2022-658152, US-MODERNATX, INC.-MOD-2022-658158, US-MODERNATX, INC.-MOD-2022-658161 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-658139:Adult patient 1 US-MODERNATX, INC.-MOD-2022-658149:Adult patient 2 US-MODERNATX, INC.-MOD-2022-658150:Adult patient 3 US-MODERNATX, INC.-MOD-2022-658154:Adult patient 5 US-MODERNATX, INC.-MOD-2022-658155:Adult patient 6 US-MODERNATX, INC.-MOD-2022-658156:Adult patient 7 US-MODERNATX, INC.-MOD-2022-658157:Adult patient 8 US-MODERNATX, INC.-MOD-2022-658159:Adult patient 10 US-MODERNATX, INC.-MOD-2022-658162:Adult patient 13 US-MODERNATX, INC.-MOD-2022-658168:Adult patient 14 US-MODERNATX, INC.-MOD-2022-658173:Adult patient 15 US-MODERNATX, INC.-MOD-2022-658152:Adult patient 4 US-MODERNATX, INC.-MOD-2022-658158:Adult patient 9 US-MODERNATX, INC.-MOD-2022-658161:Adult patient 12
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: No Adverse Event; The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021) and NO ADVERSE EVENT (No Adverse Event) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 39K20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 20-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Jan-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse Event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.            No concomitant medication information was provided.  No treatment medication was provided.   This case was linked to MOD-2022-658643 (Patient Link).
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: No Adverse Event; The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021) and NO ADVERSE EVENT (No Adverse Event) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 39K20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 20-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Jan-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021). On an unknown date, the patient experienced NO ADVERSE EVENT (No Adverse Event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patient's first dose of Moderna was on 20Dec2020 and second dose (Lot#039K20A) on 28Jan2021) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.            No concomitant medication information was provided.  No treatment medication was provided.   This case was linked to MOD-2022-658643 (Patient Link).
Age: 67.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: The vial was stored post puncture in room temperature and was administered beyond 12 hours on 13-Oct-2022; No adverse event; Received expired Bivalent Booster beyond 12 hours post puncture; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received expired Bivalent Booster beyond 12 hours post puncture), PRODUCT STORAGE ERROR (The vial was stored post puncture in room temperature and was administered beyond 12 hours on 13-Oct-2022) and NO ADVERSE EVENT (No adverse event) in a 67-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 057F22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 13-Oct-2022 at 10:45 AM, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 13-Oct-2022 at 10:45 AM,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Received expired Bivalent Booster beyond 12 hours post puncture). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was stored post puncture in room temperature and was administered beyond 12 hours on 13-Oct-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received expired Bivalent Booster beyond 12 hours post puncture), PRODUCT STORAGE ERROR (The vial was stored post puncture in room temperature and was administered beyond 12 hours on 13-Oct-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Received expired Bivalent Booster beyond 12 hours post puncture) and PRODUCT STORAGE ERROR (The vial was stored post puncture in room temperature and was administered beyond 12 hours on 13-Oct-2022).    The concomitant medication was not reported by reporter.  The Bivalent booster dose administered beyond 12 hours posts puncture. Had unbroken cartons and vial size was 2.5 ml. On an unknown date the vial was initially stored in the refrigerator in less than 30 days. On 12-Oct-2022 at 7 PM the vial was first punctured and on 13-Oct-2022 at 10:45 AM vaccine was administered. In room temperature the vial stored post puncture. The vial did not undergo any temperature excursions. In 16 hours of time the vial was exposed to room temperature range (8 to 25 degree Celsius, 46 to 77-degree F). The vial does not expose to room temperature for greater than 24 hours.  The treatment medication was not reported by reporter.
Sex: M
Vaccine: COVID19-2
Symptoms: Back pain, Oropharyngeal pain
Clinical narrative: Back pain; Sore throat; This spontaneous case was reported by a patient and describes the occurrence of BACK PAIN (Back pain) and OROPHARYNGEAL PAIN (Sore throat) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In October 2022, the patient experienced BACK PAIN (Back pain) and OROPHARYNGEAL PAIN (Sore throat). At the time of the report, BACK PAIN (Back pain) and OROPHARYNGEAL PAIN (Sore throat) outcome was unknown.            No concomitant medication was reported.    No treatment information was reported.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Administration error: 26 doses administered to adult patients from pediatric vials instead of bivalent vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Administration error: 26 doses administered to adult patients from pediatric vials instead of bivalent vaccine) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In October 2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In October 2022, the patient experienced WRONG PRODUCT ADMINISTERED (Administration error: 26 doses administered to adult patients from pediatric vials instead of bivalent vaccine). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Administration error: 26 doses administered to adult patients from pediatric vials instead of bivalent vaccine) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Administration error: 26 doses administered to adult patients from pediatric vials instead of bivalent vaccine).    Concomitant product use was not provided by the reporter. It was reported that on 08-Oct-2022, 09-Oct-2022 and 10-Oct-2022, they administered 26 doses to adult patients from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster. Treatment information was not provided. Out of 26 patients this case for patient-26.
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Wrong product administered
Clinical narrative: administered 26 doses to adult patients from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (administered 26 doses to adult patients from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (administered 26 doses to adult patients from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster) and NO ADVERSE EVENT (No adverse event). On 10-Oct-2022, WRONG PRODUCT ADMINISTERED (administered 26 doses to adult patients from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster) outcome was unknown. At the time of the report, NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (administered 26 doses to adult patients from pediatric vials of Moderna COVID-19 Vaccine instead of bivalent booster).    No relevant concomitant medications were reported.   On 8 Oct 2022, 9 Oct 2022 and 10 Oct 2022 vaccine was administered. Reporter was not aware of any AEs after the vaccines were given.   No treatment medication reported.   This case refers to 3rd patient out of 26 patients.
Age: 25.0
Sex: M
Vaccine: FLU4
Symptoms: Dyspnoea, Urticaria
Clinical narrative: Hives, dyspnea-- treated with benadryl with resolution of symptoms
Age: 83.0
Sex: F
Vaccine: COVID19-2
Symptoms: Rash
Clinical narrative: Rash on left arm,   139/78   Blood pressure Pulse    64 temp     99.9
Age: 43.0
Sex: F
Vaccine: FLUC4
Symptoms: Injection site bruising, Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling
Clinical narrative: Site: Bruising at Injection Site-Medium, Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: pt reported swelling / redness and itching at injection site
Age: 70.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: According to patient, she woke up this morning with redness and warm to touch on her injection site. When she presented to the pharmacy she stated it was a little bit better. When examined her her arm was still red and warm to touch.
Age: 70.0
Sex: F
Vaccine: PNC20
Symptoms: Fatigue, Injection site pain, Lethargy, Pain
Clinical narrative: Site: Pain at Injection Site-Mild, Systemic: Body Aches Generalized-Medium, Systemic: Exhaustion / Lethargy-Medium
Age: 92.0
Sex: F
Vaccine: FLU4
Symptoms: Syncope, Unresponsive to stimuli
Clinical narrative: Systemic: Fainting / Unresponsive-Medium, Systemic: Unresponsive for few minutes then gained response and was speaking.-Medium, Additional Details: Patient was unresponsive for a few minutes. 911 was called and checked breathing. Her daughter was with her. She gained consciousness after few minutes. She was speaking. paramedics took her to the hospital.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Lymphadenopathy, Oropharyngeal pain
Clinical narrative: Systemic: Headache-Medium, Systemic: Lymph Node Swelling-Medium, Additional Details: Patient also reported fatigue and sore throat.
Age: 45.0
Sex: F
Vaccine: COVID19-2
Symptoms: Pruritus
Clinical narrative: Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium
Age: 76.0
Sex: F
Vaccine: COVID19-2
Symptoms: Dizziness, Fall
Clinical narrative: Systemic: Dizziness / Lightheadness-Medium, Additional Details: son called to report that pt had fallen twice after receiving vaccine; first fall was later in the evening after vaccine and second was roughly 24 hours later; patient denies any other symptoms besides dizziness; son reports no injuries were sustained from either fall; son was instructed to monitor pt closely and follow up with md as soon as possible as a precaution
Age: 64.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injection site bruising
Clinical narrative: Site: Bruising at Injection Site-Medium
Age: 15.0
Sex: F
Vaccine: FLUC4
Symptoms: Dizziness, Fatigue, Injection site erythema, Injection site pain, Injection site pruritus
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Mild
Age: 15.0
Sex: F
Vaccine: FLUC4
Symptoms: Injection site swelling, Lethargy
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Mild
Age: 63.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Mild, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Mild
Age: 73.0
Sex: F
Vaccine: COVID19-2
Symptoms: Autoimmune disorder, Dyspnoea, Injection site pruritus, Lip swelling, Myasthenia gravis
Clinical narrative: Site: Itching at Injection Site-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Allergic: Rash Generalized-Mild, Systemic: Autoimmune Disease (diagnosed by MD)-Mild, Additional Details: Patient states she had hives and swelling of upper lip. Did not require epinephrine a and onset was later in the evening after vaccince. states she has myasthenia gravis and believes reaction related to this, however, reported reaction and wanted pharmacy to be aware. No MD visit reported. Patient self medicated with benadryl. No reported difficulty breathing
Age: 73.0
Sex: F
Vaccine: COVID19-2
Symptoms: Rash, Urticaria
Clinical narrative: Site: Itching at Injection Site-Mild, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Allergic: Rash Generalized-Mild, Systemic: Autoimmune Disease (diagnosed by MD)-Mild, Additional Details: Patient states she had hives and swelling of upper lip. Did not require epinephrine a and onset was later in the evening after vaccince. states she has myasthenia gravis and believes reaction related to this, however, reported reaction and wanted pharmacy to be aware. No MD visit reported. Patient self medicated with benadryl. No reported difficulty breathing
Age: 59.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injection site erythema, Injection site nodule, Injection site pain, Injection site warmth
Clinical narrative: Injection Site extended Red, warm, knot, very sore  Can provide Photo if necessary
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Wrong product administered
Clinical narrative: Error: Wrong Vaccine/Product Administered-
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain
Clinical narrative: Site: Pain at Injection Site-Medium
Age: 82.0
Sex: F
Vaccine: VARZOS
Symptoms: Confusional state, Headache, Herpes zoster, Injection site pruritus, Pruritus
Clinical narrative: Site: Itching at Injection Site-Medium, Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash Generalized-Medium, Systemic: Confusion-Mild, Systemic: Headache-Mild, Additional Details: Patient said that she had shingles rash before vaccination and almost made it sound like she was starting to get a rash prior to immunization. She reported some confusion the day after and has had rash since that is on arms, legs, and chest
Age: 82.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Site: Itching at Injection Site-Medium, Systemic: Allergic: Itch Generalized-Medium, Systemic: Allergic: Rash Generalized-Medium, Systemic: Confusion-Mild, Systemic: Headache-Mild, Additional Details: Patient said that she had shingles rash before vaccination and almost made it sound like she was starting to get a rash prior to immunization. She reported some confusion the day after and has had rash since that is on arms, legs, and chest
Age: 53.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: Error: Wrong Dose of Vaccine - Too Low-
Age: 72.0
Sex: F
Vaccine: FLU4
Symptoms: Extra dose administered, No adverse event
Clinical narrative: patient received the high dose flu on 9/28/2022 and then requested again and received the same medication on 10/7/2022. Patient has reported no adverse effects following the second dose
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect product formulation administered
Clinical narrative: Pt was given the Monovalent pfizer vaccine instead of the BiValent. called patient to inform them
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Impaired work ability, Loss of personal independence in daily activities, Lymphadenopathy
Clinical narrative: Myalgias, arthralgias, low grade fever, headaches, generalized lymphadenopathy (axillary, epitrochlear, cervical). I had similar reaction to 3 prior doses of Pfizer, except lymphadenopathy was new with dose 4). Onset of symptoms was within a few hours with each dose, lasting 3-5 days, unable to work or do usual activities.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Myalgias, arthralgias, low grade fever, headaches, generalized lymphadenopathy (axillary, epitrochlear, cervical). I had similar reaction to 3 prior doses of Pfizer, except lymphadenopathy was new with dose 4). Onset of symptoms was within a few hours with each dose, lasting 3-5 days, unable to work or do usual activities.
Age: 37.0
Sex: F
Vaccine: UNK
Symptoms: Dizziness, Headache, Vomiting
Clinical narrative: HEADACHE WITH VOMITING. DIZZINESS.
Age: 70.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID BREAKTHROUGH CASE
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Moderna 3/4/21, 4/1/21. Positive on 10/16/22
Age: 95.0
Sex: F
Vaccine: FLUA4
Symptoms: Extra dose administered
Clinical narrative: The patient received 2 flu vaccines this season.  She received her first on 9/22/22.  She did not remember that she had already received it and came to a flu clinic in her senior living community and got another one.  Upon processing her shot in the dispensing system, we realized that she had already been vaccinated for the flu.
Age: 26.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: gave .25cc instead of .5cc
Age: 59.0
Sex: F
Vaccine: FLUR4
Symptoms: Burning sensation, Pruritus, Swelling
Clinical narrative: Itching, burning, swelling. Patient reports history of egg allergy.
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: GAVE .25CC INSTEAD OF .5CC
Age: 55.0
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, Underdose
Clinical narrative: GAVE .25CC INSTEAD OF .5CC
Age: 67.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: gave .25cc instead of .5cc
Age: 56.0
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: gave .25cc instead of .5cc
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Pain, Rhinorrhoea
Clinical narrative: RUNNY NOSE, COUGH, ACHES
Age: 60.0
Sex: M
Vaccine: COVID19-2
Symptoms: Incorrect dose administered
Clinical narrative: gave .25cc instead of .5cc
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Dizziness, Hyperhidrosis, Pallor
Clinical narrative: Individual stated she was feeling pressure on left lateral neck and left forearm. Diaphoretic, pale and almost fainted. Given 200mg Motrin and recovered.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID BREAKTHROUGH CASE
Age: 33.0
Sex: M
Vaccine: SMALLMNK
Symptoms: Abdominal discomfort, Diarrhoea, Nausea
Clinical narrative: Severe Nausea and GI discomfort.  Diarrhea
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Headache, Hyperhidrosis, Hypersensitivity, Vomiting
Clinical narrative: PT. EXPERIENCED MAJOR HEADACHE,VOMITING, STOMACH PAIN, SWEATING,  Per Facility nurse patient was experiencing a severe allergic reaction.  UNABLE TO TELL EMT WHAT YEAR WE ARE IN (2019). EMT CALLED AND PT. TAKEN TO LOCAL HOSPITAL
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Alanine aminotransferase normal, Albumin globulin ratio, Anion gap, Aspartate aminotransferase normal, Basophil count normal
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Basophil percentage, Bell's palsy, Blood albumin normal, Blood alkaline phosphatase normal, Blood bilirubin normal
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Blood calcium normal, Blood chloride normal, Blood creatinine normal, Blood glucose normal, Blood potassium normal
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Blood sodium normal, Blood urea nitrogen/creatinine ratio, Blood urea normal, Carbon dioxide normal, Condition aggravated
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Decreased nasolabial fold, Differential white blood cell count abnormal, Electrocardiogram, Eosinophil count normal, Eosinophil percentage increased
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Facial paralysis, Full blood count abnormal, Globulin, Glomerular filtration rate normal, Granulocyte percentage
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Haematocrit normal, Haemoglobin normal, Hypertension, Immature granulocyte count, Lymphocyte count
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Lymphocyte percentage, Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume normal, Mean platelet volume increased
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Metabolic function test, Mobility decreased, Monocyte count, Monocyte percentage increased, Muscle contractions involuntary
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Neutrophil count, Neutrophil percentage, Platelet count normal, Protein total normal, Red blood cell count normal
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 54.0
Sex: M
Vaccine: COVID19-2, FLUC4
Symptoms: Red blood cell nucleated morphology, Red cell distribution width, White blood cell count normal
Clinical narrative: On the Evening of October 1, 2022 , following the two vaccines described above (on September 30, 2022) I noticed left sided changes in muscle contractions in my neck without pain. That progressed to mild left sided paralysis in my face on Monday October 3rd, 2022. I wen to the emergency room and was diagnosed with mild Bell's Palsy.
Age: 12.0
Sex: F
Vaccine: FLU4
Symptoms: Electrocardiogram normal, Heart rate increased, Heart rate irregular, Hypoaesthesia, Paraesthesia
Clinical narrative: Mom said the night of admin of vaccine, felt numbness and tingling sensation in fingers and toes. Whole hand and foot then begin to feel numbness. Trembling and shaking in legs. Torso was shaking as well. Took to ED, everything was okay, vitals were okay, not concern. On the way to the hospital, mom said heart rate was high and skipping beats, they ran EKG and everything was okay.
Age: 12.0
Sex: F
Vaccine: FLU4
Symptoms: Tremor
Clinical narrative: Mom said the night of admin of vaccine, felt numbness and tingling sensation in fingers and toes. Whole hand and foot then begin to feel numbness. Trembling and shaking in legs. Torso was shaking as well. Took to ED, everything was okay, vitals were okay, not concern. On the way to the hospital, mom said heart rate was high and skipping beats, they ran EKG and everything was okay.
Age: 37.0
Sex: F
Vaccine: YF
Symptoms: Injection site rash, Rash erythematous, Rash pruritic, Skin warm
Clinical narrative: Patient emailed this nurse stating  she noticed a red rash near injection site on 10/16/2022. States the rash is itchy an slightly warm. She denies any fevers, SOB, nausea, vomiting, diarrhea, an body aches. Communication has been sent to  provider regarding this.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Decreased appetite, Dizziness, Fatigue, Headache, Pyrexia
Clinical narrative: Headache, dizziness, fatigue, fever and loss of appetite
Age: 28.0
Sex: F
Vaccine: FLU4, VARCEL
Symptoms: Dizziness, Erythema, Injection site erythema, Injection site nodule, Injection site swelling
Clinical narrative: Pt received varicella vaccination subQ in the back of her right arm; the next morning, the injection site was red and swollen, with a small knot. Pt states it continued to get worse throughout the day and extended around entire arm. Pt also became dizzy and lightheaded.
Age: 28.0
Sex: F
Vaccine: FLU4, VARCEL
Symptoms: Peripheral swelling
Clinical narrative: Pt received varicella vaccination subQ in the back of her right arm; the next morning, the injection site was red and swollen, with a small knot. Pt states it continued to get worse throughout the day and extended around entire arm. Pt also became dizzy and lightheaded.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Headache, Nausea, Vision blurred, Vomiting
Clinical narrative: Flushing, nausea, vomiting, headache, blurred vision. Given Benadryl 25mg and Pepcid 20mg and sent to ER.
Age: 31.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site pruritus, Injection site swelling
Clinical narrative: itching and swelling at site of injection for 2 days.  Zyrtec and Singular taken for itching and swelling. Recovered after 2 days.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Vomiting
Clinical narrative: Vomiting x4 times, headache. Given Tylenol 650mg and Zofran 4mg  x1. PT went home to rest.
Age: 3.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: Paper work (incident/near miss report)completed and sent to risk management.  Provider also informed and to contact patient.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Breast pain, Musculoskeletal chest pain
Clinical narrative: I started having pain in my underarm and on my side of my left breast not really swollen but a lot of pain. Pain is mostly around my rib cage on my left side, like a constant ache but sometimes sharp.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Patient vaccinated against, then tested positive for COVID-19
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  dose 1 Moderna 3/11/21  040A21A dose 2 Moderna 4/8/21  045A21A
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: break through Covid